Premier Biomedical, Inc. has received approval from the United States Patent Office for their proprietary medication “Feldetrex,” a drug designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is now drafting a protocol in order to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns, which will be submitted for IRB approval shortly.
William A. Hartman, President and CEO of Premier Biomedical, stated, “We are very excited that the United States Patent Office granted our request for a patent on Feldetrex ™. We are very confident in our ability to perform well in the upcoming double-blind clinical study because of the favorable responses we have received to date from the limited number of patients that have taken the medication thus far. We are applying for FDA approval immediately and are also confident that our application will be approved, since Feldetrex ™ consists only of a skillful and proprietary combination of FDA-approved ingredients.”
He added that “the market for such a medication worldwide runs into many billions of dollars. We believe that our medication will also fare very well versus competition due to its projected lack of serious side effects. The market should see results very quickly as the double-blind study is tentatively scheduled to be concluded later this calendar year.”
Premier Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies. Its target diseases include breast cancer, Alzheimer’s, multiple sclerosis (MS), and traumatic brain injury (TBI).